Platelet-rich plasma (PRP) is blood plasma that has been enriched with platelets. As a concentrated source of autologous platelets, PRP contains several different growth factors and other cytokines that can stimulate healing of soft tissue. Platelet rich plasma therapy utilizes growth factors present in alpha granules of platelets in an autologous manner. The efficacy of certain growth factors in healing various injuries and the concentrations of these growth factors found within PRP are the theoretical basis for the use of PRP in tissue repair. The platelets collected in PRP are activated by the addition of thrombin and calcium chloride, which induces the release of the mentioned factors from alpha granules.
AlloGen™ is a multipurpose, frozen allograft derived from amniotic fluid. Just as amniotic fluid protects and nourishes the fetus during development, AlloGen provides the same protection to injured or traumatized tissue. Amniotic fluid contains various proteins that support cell proliferation, movement and differentiation. Amniotic fluid also includes collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, extracellular matrix molecules like hyaluronic acid and fibronectin, cells and other chemical compounds that are needed for tissue protection and repair.
Amniotic fluid is rich in the components that are believed to contribute to a wound healing response characterized by minimal inflammatory activity and regenerative rather than scar-mediated healing. These components work to kick-start the body’s own rejuvenation and healing process. As an all-natural liquid matrix, AlloGen Amniotic Fluid Therapy (AFT)™ can be easily applied directly at the site of injury, inflammation and pain.
Human amniotic membrane is a unique, thin, collagenous membrane derived from the placenta, the area in which the human fetus grows and develops within the mother’s uterus. Human amniotic membrane consists of collagen layers including basement membrane and stromal matrix.
Injectable amniotic membrane is a minimally manipulated, dehydrated, nonviable cellular amniotic membrane allograft that contains multiple extracellar matrix proteins, growth factors, cytokines and other specialty proteins present in amniotic tissue to help regenerate soft tissue.
The unique biologic structure of placental tissue contains the structure, signals and cells required to protect the fetus aid in fetal growth and development. In addition to its structural properties, the placental membrane and amniotic fluid have been found to contain a rich source of proteins, cytokines, growth factors and other chemical compounds, all of which are essential for fetal growth and development. Amniotic fluid also contains multipotent cells that are capable of differentiating into all three germ layers of the human body. Specifically, amniotic fluid derived stem cells have been shown to be broadly multipotent, capable of differentiating into adipogenic, osteogenic, myogenic, endothelial, neurogenic and hepatic cell lineages. The presence of residual multipotent cells naturally present in amnion may provide ancillary clinical benefits to the patient.
Amniotic tissue is an abundant source of collagen that provides an extracellular matrix to act as a natural scaffold for cellular attachment in the body. Collagen provides a structural tissue that facilitates, among other things, cell migration and proliferation in vivo. BioDFactor was developed using a proprietary technique that morselizes the amnion in an effort to preserve its structural properties in an injectable form. This “micro-scaffold” created by the morselized tissue matrix includes the residual proteins, carbohydrates, hyaluronic acid, growth factors and other chemical compounds naturally present in amniotic fluid and tissue to provide a liquid tissue matrix that is derived from those components essential for fetal growth and development.
Amniotic membrane is a unique human tissue in that it rarely evokes an immune response in the human body. The unique biologic structure of amniotic tissue, coupled with the low risk of an immune response, makes BioDFactor an ideal choice for homologous clinical use.